Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02144038
Recruitment Status : Completed
First Posted : May 21, 2014
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a Phase Ib/II study with the primary purpose of the Phase Ib part being to estimate the MTD and/or recommended phase 2 dose (RP2D) of the combination of LGH447 and BYL719 when administered orally to adult patients with relapsed and refractory multiple myeloma. Once the MTD and/or RP2D is determined for the combination of LGH447 and BYL719, additional patients will be enrolled in the Phase II part to determine whether the combination of LGH447 and BYL719 exhibits improved anti-multiple myeloma activity compared to single agent LGH447. This trial never made it to the Phase II part of the this trial.

Condition or disease Intervention/treatment Phase
Relapsed and Refractory Multiple Myeloma Drug: LGH447 Drug: BYL719 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Actual Study Start Date : July 23, 2014
Actual Primary Completion Date : October 28, 2015
Actual Study Completion Date : October 28, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Phase Ib: LGH447 + BYL719
Dose-escalation, LGH447 in combinatinon with BYL719
Drug: LGH447
pan-PIM inhibitor

Drug: BYL719
PI3K-alpha inhibitor

Experimental: Phase II: LGH447 + BYL719
LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
Drug: LGH447
pan-PIM inhibitor

Drug: BYL719
PI3K-alpha inhibitor

Experimental: Phase II: LGH447 alone
LGH447 alone (dosing according to single-agent RDE)
Drug: LGH447
pan-PIM inhibitor




Primary Outcome Measures :
  1. Phase Ib: Number of Total Dose-limiting Toxicities (DLT) [ Time Frame: Cycle 1 (28 days) ]
    Using a Bayesian logistic regression model (BLRM) to guide dose escalation and predict MTD or determine the RP2D for LGH447 in combination with BYL719 in relapsed and refractory multiple myeloma. The frequency and characteristics of DLTs will be assessed.

  2. Phase II: Overall Response Rate (ORR) as assessed by Investigators [ Time Frame: 29 months (End of Study) ]

    The proportion of patients with a confirmed best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as assessed by Investigators using the International Myeloma Working group (IMWG) Criteria with modifications.

    End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.



Secondary Outcome Measures :
  1. Phase II: Percent change of ORR (Overall Response Rate) between the two arms [ Time Frame: 29 months (End of Study) ]
    The ORR percent change between the two arms, LGH447 in combination with BYL719 and LGH447 alone, is the parameter of interest. Both observed and Bayesian estimates of ORR percent change along with 80% confidence intervals and credible intervals will be calculated. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

  2. Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability. [ Time Frame: 23 months ]
    Assessments consisted of recording all adverse events (AEs) and serious adverse events (SAEs), the regular monitoring of hematology, blood chemistry, urinalysis, and coagulation parameters, as well as electrocardiograms.

  3. Determine single and multiple dose Pharmacokinetics (PK) profiles [ Time Frame: Approximately 8 months ]
    To determine the single and multiple dose PK profiles of the LGH447 and BYL719 combination (Phase Ib and II) and LGH447 alone (Phase II), by measuring plasma concentrations of LGH447 and BYL719 respectively at different timepoints prior and post study drug combination dosing on several days within cycle 1 and subsequent cycles for all patients in the Phase 1b and for the first 15 patients in each arm in the Phase 2 portion of the study. PK parameters including but not limited to Cmax, AUCinf, AUClast, AUCtau,T1/2, Tmax, Racc, CL/F, and Vz/F

  4. Changes between pre- and post-treatment levels of pS6RP and 4EBP1 levels in bone marrow aspirates and 4EBP1 in peripheral blood [ Time Frame: baseline, Cycle 2 Day 1 ]
    Cycle 2 = 28 days; LGH447-mediated target modulation of the PIM pathway will be assessed from the collection of bone marrow biopsy and/or aspirates by flow cytometry, immunohistochemistry, or other methods as deemed appropriate. Decreases in the phosphorylation of markers (eg. S6RP and 4EBP1) will be measured in both pre- and post-dose bone marrow aspirate samples and peripheral blood samples.

  5. Phase II: Absolute difference in ORR [ Time Frame: 29 months (End of Study) ]
    Both observed and Bayesian estimates of absolute difference in ORR between the two arms will be calculated. The 80% confidence intervals and credible intervals for the difference will be provided. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

  6. Disease Control Rate [ Time Frame: 29 months (End of Study) ]
    Proportion of patients with a best overall response of sCR, CR, VGPR, PR, MR, or SD, using International Myeloma Working Group Criteria with modification. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

  7. Progression Free Survival [ Time Frame: 29 months (End of Study) ]
    Defined as the time from start of treatment to the date of event defined as the first documented PD/relapse, or death due to any cause, whichever comes first. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

  8. Time to response [ Time Frame: 29 months (End of Study) ]
    The time between date of randomization until first documented best overall response (sCR, CR, VPGR or PR). End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.

  9. Duration of Response [ Time Frame: 29 months (End of Study) ]
    Defined as the duration from the first documented onset of PR or better response to the date of documented PD/relapse or death due to multiple myeloma. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Patients with a confirmed diagnosis of multiple myeloma who have received two or more lines of therapy and are refractory to their most recent line of therapy, as defined as relapse while on therapy or within 60 days from their last line of therapy. If patient has not received either an immunomodulatory drug (IMID) or proteasome inhibitor as a prior therapy then Investigator must notify Novartis prior to the patient enrollment. Patients who have received a prior bone marrow transplant and otherwise meet the inclusion criteria are eligible for this study
  • For patients in the Phase II portion of the study, must have measurable disease defined by at least 1 of the following 3 measurements:

    • Serum M-protein ≥ 0.5 g/dL
    • Urine M-protein ≥ 200 mg/24 hours OR
    • Serum free light chain (FLC) > 100 mg/L of involved FLC
  • All patients must be willing to undergo a mandatory bone marrow aspirate and/or biopsy at baseline for the assessment of biomarker/pharmacodynamics and disease status

Exclusion Criteria:

  • Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of either study drug
  • Radiotherapy within 14 days before the first dose of either study drug except localized radiation therapy for lytic bone lesions and plasmacytomas
  • Major surgery within 2 weeks before the first dose of either study drug
  • Ongoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ≤ 10 mg or an equivalent steroid dose), inhaled and topical steroids are permitted
  • Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:
  • Narrow Therapeutic index substrates, strong inhibitors and strong inducers of CYP3A4
  • Strong Inhibitors of CYP2D6
  • Narrow therapeutic index substrates of CYP2C8, CYP2C9, CYP2C19 and CYP2D6
  • Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of either study drug):
  • Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
  • Platelet count < 75,000 mm3 without transfusion support within 7 days prior to testing
  • Bilirubin > 1.5 times the upper limit of the normal range (ULN).
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
  • Calculated creatinine clearance < 30 ml/min according to Cockcroft-Gault equation
  • Corrected QT interval (QTc) of > 450 milliseconds (ms) in males and > 470 milliseconds (ms) in females on baseline electrocardiogram (ECG) (using Fridericia [QTcF] corrected QT interval

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02144038


Locations
Layout table for location information
United States, Texas
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC)
Houston, Texas, United States, 77030-4009
United States, Washington
Seattle Cancer Care Alliance Oncology Dept
Seattle, Washington, United States, 98105
United States, Wisconsin
University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc.
Madison, Wisconsin, United States, 53792-6164
Australia, Victoria
Novartis Investigative Site
Prahran, Victoria, Australia, 3181
Germany
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Kiel, Germany, 24105
Italy
Novartis Investigative Site
Milano, MI, Italy, 20133
Singapore
Novartis Investigative Site
Singapore, Singapore, 169608
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02144038     History of Changes
Other Study ID Numbers: CLGH447X2103C
2013-004959-21 ( EudraCT Number )
First Posted: May 21, 2014    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: April 2018

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
multiple myeloma,
relapsed and refractory,
LGH447,
pan-PIM inhibitor,
PIM Kinase,
BYL719,
PI3K inhibitor

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases